Aldeyra Therapeutics Company Profile (NASDAQ:ALDX)

About Aldeyra Therapeutics (NASDAQ:ALDX)

Aldeyra Therapeutics logoAldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALDX
  • CUSIP: N/A
  • Web: www.aldeyra.com
Capitalization:
  • Market Cap: $73.77 million
  • Outstanding Shares: 6,245,000
Average Prices:
  • 50 Day Moving Avg: $4.77
  • 200 Day Moving Avg: $4.87
  • 52 Week Range: $3.80 - $8.19
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.34
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.85 per share
  • Price / Book: 2.58
Profitability:
  • EBIDTA: ($18,790,000.00)
  • Return on Equity: -71.82%
  • Return on Assets: -63.38%
Debt:
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 13.11%
  • Quick Ratio: 13.11%
Misc:
  • Average Volume: 114,589 shs.
  • Beta: 0.3
  • Short Ratio: 1.98
 

Frequently Asked Questions for Aldeyra Therapeutics (NASDAQ:ALDX)

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) released its earnings results on Monday, May, 15th. The company reported ($0.37) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.04. View Aldeyra Therapeutics' Earnings History.

When will Aldeyra Therapeutics make its next earnings announcement?

Aldeyra Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 8th 2017. View Earnings Estimates for Aldeyra Therapeutics.

Where is Aldeyra Therapeutics' stock going? Where will Aldeyra Therapeutics' stock price be in 2017?

4 brokerages have issued 12 month price targets for Aldeyra Therapeutics' stock. Their forecasts range from $12.00 to $20.00. On average, they expect Aldeyra Therapeutics' share price to reach $16.50 in the next year. View Analyst Ratings for Aldeyra Therapeutics.

What are analysts saying about Aldeyra Therapeutics stock?

Here are some recent quotes from research analysts about Aldeyra Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. " (5/30/2017)
  • 2. Cowen and Company analysts commented, "On its 4Q call, ALDX announced the Feb start of the planned ADX-102 Ph2b allergic." (3/31/2017)

Who are some of Aldeyra Therapeutics' key competitors?

Who are Aldeyra Therapeutics' key executives?

Aldeyra Therapeutics' management team includes the folowing people:

  • Todd Brady M.D., President, Chief Executive Officer, Director
  • Stephen J. Tulipano CPA, Chief Financial Officer, Treasurer
  • Scott L Young, Chief Operating Officer
  • David J. Clark M.D., Chief Medical Officer
  • Ben Bronstein M.D., Director
  • Jesse I. Treu Ph.D., Director
  • Richard H. Douglas Ph.D., Independent Director
  • Martin J. Joyce, Independent Director
  • Gary M. Phillips M.D., Independent Director

How do I buy Aldeyra Therapeutics stock?

Shares of Aldeyra Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aldeyra Therapeutics' stock price today?

One share of Aldeyra Therapeutics stock can currently be purchased for approximately $4.78.


MarketBeat Community Rating for Aldeyra Therapeutics (NASDAQ ALDX)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  145
MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aldeyra Therapeutics (NASDAQ:ALDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.50 (245.15% upside)

Analysts' Ratings History for Aldeyra Therapeutics (NASDAQ:ALDX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/14/2017Canaccord GenuitySet Price TargetBuy$12.00LowView Rating Details
6/15/2017HC WainwrightSet Price TargetBuy$18.00LowView Rating Details
5/31/2017Stifel NicolausReiterated RatingBuy$16.00MediumView Rating Details
3/31/2017Cowen and CompanyReiterated RatingBuy$20.00LowView Rating Details
2/29/2016Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
(Data available from 7/21/2015 forward)

Earnings

Earnings History for Aldeyra Therapeutics (NASDAQ:ALDX)
Earnings by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)
Earnings History by Quarter for Aldeyra Therapeutics (NASDAQ ALDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017($0.39)N/AView Earnings Details
5/15/2017Q1 2017($0.33)($0.37)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.66)($0.36)ViewN/AView Earnings Details
11/14/2016Q316($0.39)($0.38)ViewN/AView Earnings Details
8/10/2016Q216($0.44)($0.41)ViewListenView Earnings Details
5/9/2016Q116($0.50)($0.51)ViewN/AView Earnings Details
11/12/2015Q315($0.29)($0.35)ViewListenView Earnings Details
8/11/2015Q215($0.35)($0.27)ViewListenView Earnings Details
5/13/2015Q115($0.39)($0.32)ViewListenView Earnings Details
4/14/2015($0.39)($0.31)ViewN/AView Earnings Details
11/10/2014Q314($0.32)($0.36)ViewN/AView Earnings Details
8/4/2014Q214($0.53)($1.56)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aldeyra Therapeutics (NASDAQ:ALDX)
Current Year EPS Consensus Estimate: $-1.49 EPS
Next Year EPS Consensus Estimate: $-1.43 EPS

Dividends

Dividend History for Aldeyra Therapeutics (NASDAQ:ALDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aldeyra Therapeutics (NASDAQ:ALDX)
Insider Ownership Percentage: 28.40%
Institutional Ownership Percentage: 58.25%
Insider Trades by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)
Institutional Ownership by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)
Insider Trades by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/30/2017Life Sciences Maste PerceptiveMajor ShareholderBuy296,007$4.60$1,361,632.20View SEC Filing  
2/17/2017Martin Joseph JoyceDirectorBuy4,444$4.50$19,998.00View SEC Filing  
2/17/2017Stephen J TulipanoCFOBuy3,333$4.50$14,998.50View SEC Filing  
2/17/2017Todd C BradyInsiderBuy22,223$4.50$100,003.50View SEC Filing  
2/14/2017Perceptive Advisors LlcMajor ShareholderBuy893,025$4.50$4,018,612.50View SEC Filing  
5/26/2016Perceptive Advisors LlcMajor ShareholderBuy700,000$5.00$3,500,000.00View SEC Filing  
10/26/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.46$323,000.00View SEC Filing  
10/22/2015Perceptive Advisors LlcMajor ShareholderBuy18,020$6.47$116,589.40View SEC Filing  
10/20/2015Perceptive Advisors LlcMajor ShareholderBuy37,145$6.39$237,356.55View SEC Filing  
8/7/2014Martin Joseph JoyceDirectorBuy1,000$3.95$3,950.00View SEC Filing  
8/6/2014C. Boyd ClarkeDirectorBuy3,000$3.69$11,070.00View SEC Filing  
5/7/2014C. Boyd ClarkeDirectorBuy12,500$8.00$100,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Aldeyra Therapeutics (NASDAQ:ALDX)
Latest Headlines for Aldeyra Therapeutics (NASDAQ:ALDX)
Source:
DateHeadline
finance.yahoo.com logoAldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2a Clinical Trial
finance.yahoo.com - July 18 at 5:11 PM
americanbankingnews.com logoAldeyra Therapeutics, Inc. (NASDAQ:ALDX) Major Shareholder Life Sciences Maste Perceptive Buys 296,007 Shares
www.americanbankingnews.com - July 5 at 7:06 PM
americanbankingnews.com logoZacks: Brokerages Expect Aldeyra Therapeutics, Inc. (ALDX) Will Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - June 27 at 6:23 PM
finance.yahoo.com logoAldeyra Therapeutics to Present Novel Data on the Anti-Inflammatory Mechanism and Activity of ADX-102 at the World Congress on Inflammation 2017 Annual Meeting
finance.yahoo.com - June 19 at 3:30 PM
americanbankingnews.com logoCanaccord Genuity Analysts Give Aldeyra Therapeutics, Inc. (ALDX) a $12.00 Price Target
www.americanbankingnews.com - June 15 at 11:20 PM
rttnews.com logoKeep An Eye On ALDX Today
www.rttnews.com - June 15 at 1:31 AM
finance.yahoo.com logoAldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing
finance.yahoo.com - June 14 at 3:29 PM
finance.yahoo.com logoAldeyra Therapeutics stock drops 16% after mid-stage trial miss
finance.yahoo.com - June 14 at 3:29 PM
finance.yahoo.com logoAldeyra Stumbles Over Mid-Stage Clinical Results
finance.yahoo.com - June 14 at 3:29 PM
finance.yahoo.com logoAldeyra Therapeutics Schedules Conference Call and Webcast to Announce Results from Allergic Conjunctivitis Phase 2b Clinical Trial
finance.yahoo.com - June 13 at 8:29 PM
streetinsider.com logoAldeyra Therapeutics (ALDX) Says First Patient Enrolled in Dry Eye Disease Phase 2a Trial
www.streetinsider.com - June 8 at 9:09 PM
finance.yahoo.com logoAldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial
finance.yahoo.com - June 6 at 9:51 AM
streetinsider.com logoAldeyra Therapeutics (ALDX) Enters $20M ATM Offering Agreement
www.streetinsider.com - June 3 at 2:38 AM
americanbankingnews.com logoZacks: Analysts Anticipate Aldeyra Therapeutics Inc (ALDX) to Post -$0.41 Earnings Per Share
www.americanbankingnews.com - June 1 at 2:22 PM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Stock Rating Reaffirmed by Stifel Nicolaus
www.americanbankingnews.com - May 31 at 12:34 PM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 30 at 8:20 PM
finance.yahoo.com logoRoche (RHHBY) Presents Positive Data on IPF Drug Esbriet
finance.yahoo.com - May 26 at 3:41 PM
finance.yahoo.com logoAldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting
finance.yahoo.com - May 17 at 12:31 PM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Announces Earnings Results
www.americanbankingnews.com - May 16 at 12:26 PM
baystreet.ca logoInvestor Network: Aldeyra Therapeutics, Inc. to Host Earnings Call
www.baystreet.ca - May 15 at 3:26 PM
americanbankingnews.com logo-$0.33 Earnings Per Share Expected for Aldeyra Therapeutics Inc (ALDX) This Quarter
www.americanbankingnews.com - May 8 at 12:20 PM
finance.yahoo.com logoAldeyra Therapeutics Schedules Webcast and Conference Call to Provide Corporate Update and First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 11:11 AM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - May 5 at 9:14 PM
americanbankingnews.com logoAldeyra Therapeutics (ALDX) Given Daily Media Sentiment Rating of -0.29
www.americanbankingnews.com - May 2 at 9:24 AM
americanbankingnews.com logoAldeyra Therapeutics (ALDX) Receiving Negative News Coverage, Report Shows
www.americanbankingnews.com - April 28 at 9:00 AM
finance.yahoo.com logoAldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase 3 Clinical Trial
finance.yahoo.com - April 27 at 3:49 PM
americanbankingnews.com logoAldeyra Therapeutics (ALDX) Receives Daily News Impact Rating of 0.44
www.americanbankingnews.com - April 24 at 12:18 PM
streetinsider.com logoAldeyra Therapeutics (ALDX) Confirms FDA Orphan Drug Designation for ADX-102 in Sjögren-Larsson
www.streetinsider.com - April 22 at 10:43 AM
americanbankingnews.com logoPositive Press Coverage Very Unlikely to Affect Aldeyra Therapeutics (ALDX) Stock Price
www.americanbankingnews.com - April 21 at 10:07 AM
finance.yahoo.com logoAldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome
finance.yahoo.com - April 20 at 3:31 PM
streetinsider.com logoAldeyra Therapeutics (ALDX) Doses Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial
www.streetinsider.com - April 19 at 7:22 AM
finance.yahoo.com logoAldeyra Therapeutics, Inc. Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial
finance.yahoo.com - April 18 at 3:27 PM
americanbankingnews.com logo Brokerages Anticipate Aldeyra Therapeutics Inc (ALDX) to Post -$0.33 Earnings Per Share
www.americanbankingnews.com - April 17 at 11:52 AM
americanbankingnews.com logoAldeyra Therapeutics (ALDX) Given Media Sentiment Rating of 0.28
www.americanbankingnews.com - April 17 at 11:41 AM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 8 at 12:50 PM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Earns Buy Rating from Cowen and Company
www.americanbankingnews.com - April 6 at 8:10 AM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Given a $18.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 3 at 12:45 AM
seekingalpha.com logoAldeyra Therapeutics' (ALDX) CEO Todd Brady on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 31 at 3:34 PM
americanbankingnews.com logoCowen and Company Reaffirms "Buy" Rating for Aldeyra Therapeutics Inc (ALDX)
www.americanbankingnews.com - March 31 at 1:43 PM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Earns Buy Rating from Canaccord Genuity
www.americanbankingnews.com - March 31 at 1:43 PM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Releases Earnings Results
www.americanbankingnews.com - March 31 at 10:11 AM
biz.yahoo.com logoQ4 2016 Aldeyra Therapeutics Inc Earnings Release - Before Market Open
biz.yahoo.com - March 30 at 3:51 PM
finance.yahoo.com logoAldeyra Therapeutics Reports Full Year 2016 Financial Results
finance.yahoo.com - March 30 at 3:51 PM
finance.yahoo.com logo8:04 am Aldeyra Therapeutics reports FY16 results
finance.yahoo.com - March 30 at 3:51 PM
biz.yahoo.com logoALDEYRA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
biz.yahoo.com - March 30 at 3:51 PM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 30 at 9:09 AM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 27 at 8:42 PM
americanbankingnews.com logoAldeyra Therapeutics Inc (ALDX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - March 24 at 9:44 AM
finance.yahoo.com logoAldeyra Therapeutics Schedules Webcast and Conference Call for Full Year 2016 Financial Results
finance.yahoo.com - March 22 at 3:29 PM
finance.yahoo.com logoAldeyra Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - February 28 at 8:55 AM

Social

Chart

Aldeyra Therapeutics (ALDX) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff